Glioblastoma is the most common, aggressive and deadly form of brain cancer. Median overall survival for primary glioblastoma is 14.6 months with the standard treatments of surgery, radiation therapy and the chemotherapy temozolomide, and falls to 5.5 – 11 months for recurrent glioblastoma.
Tumor heterogeneity and the blood-brain barrier make it difficult to treat glioblastoma. Immunotherapies such as immune checkpoint inhibitors...
